Qui sommes-nous ? About us
L'ANSM en bref
About us
Nos engagements
Nos missions
Notre périmètre
Notre organisation
Déontologie et transparence
Publications institutionnelles
Publications scientifiques
Rejoignez-nous !
Notre agenda
 
Actualités
Nos articles
Nos campagnes
 
Bulletin officiel des actes, décisions et avis
Décisions institutionnelles
Décisions liées aux médicaments
Décisions liées aux produits sanguins et autres produits biologiques
Décisions liées aux médicaments dérivés du plasma
Décisions liées aux dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
Injonctions
Décisions de police sanitaire
Sanctions financières
Avis
 
Disponibilité des produits de santé
Médicaments
Dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
 
Vos démarches
Industriel
Organismes notifiés
Professionnel de santé
Patient
Chercheur

Our organisation

A+ A-
> Consultez la version française

Two bodies are tasked with ANSM’s governance: a Management Board, and a Scientific Board.

In addition, since 2019, the Agency’s policy of openness to civil society has resulted in healthcare system users being systematically involved in our consultative bodies of expertise. We are convinced of the need to work alongside patients and healthcare professionals to ensure that our action addresses the challenges that they face on a daily basis.

For this reason, our decisions are based on the opinions of several consultative committees, in which the expertise of representatives of civil society, their perspective, and their vision of the health sector allow objective and informed decision-making.
 

French Pharmacopoeia Committees


All members of our advisory bodies are subject to the ANSM's ethical rules. The composition of these committees, the agendas and meeting minutes are published on the ANSM's website. The ANSM’s policy of openness to society as a whole is also reflected in the live broadcasting of filmed public hearings on the agency's YouTube channel.

The French Pharmacopoeia Committees participate in the drafting of monographs detailing the control methods to be applied to:
  • starting materials;
  • preparations for pharmaceutical use.
It is on the basis of these indications that pharmaceutical companies control the batches they produce at different stages in the manufacturing chain, thereby ensuring a continuous and optimal level of quality. The members of the French pharmacopoeia committees are appointed by the ANSM's Director General for a three-year term, renewable once.
 
Consult public conflict-of-interest statements - DPI Santé website
 
Consult public conflict-of-interest statements prior to 06/02/2018

List of French Pharmacopoeia Committees

  • Medicinal Plants, Essential Oils and Homeopathy
  • Biological Products and Advanced Therapy Medicinal Products
  • Chemical, Pharmaceutical and Radiopharmaceutical Substances and Preparations - Galenics
The Pharmacopoeia, the reference for medicinal products
  • The Pharmacopoeia is an official regulatory publication that defines the purity criteria for starting materials or preparations used in the manufacture of medicinal products (for human and veterinary use), and even their containers, as well as the analysis methods to be used to ensure their control.
  • It is a reference tool for healthcare professionals : users of pharmaceutical starting materials, quality control laboratories, drug registration departments and retail pharmacies.
  • The latest edition of the French Pharmacopoeia (which came into force in July 2012) is accessible, free of charge, online: French Pharmacopoeia, 11th edition.
  • The currently applicable European Pharmacopoeia is the 10th edition. In France, application of the French and European Pharmacopoeias is compulsory.